首页>
外文期刊>clinical drug investigation
>A Two-Month Comparison of Salmeterolsol;Beclomethasone and Slow-Release Terbutalinesol;Budesonide in Moderate Asthma Management
【24h】
A Two-Month Comparison of Salmeterolsol;Beclomethasone and Slow-Release Terbutalinesol;Budesonide in Moderate Asthma Management
展开▼
机译：A Two-Month Comparison of Salmeterolsol;Beclomethasone and Slow-Release Terbutalinesol;Budesonide in Moderate Asthma Management
The recommendations, according to international guidelines, for moderate asthma poorly controlled by inhaled corticosteroid therapy (800 to 1000 mgr;gsol;day) - Step Three asthma - is a combination treatment strategy consisting of a long-acting bronchodilator plus an inhaled corticosteroid. This comparative multicentre, randomised, open, parallel-group study was designed to compare salmeterol (50mgr;g twice daily) plus; beclomethasone dipropionate (BDP) lsqb;500mgr;g twice dailyrsqb; (both administered via metered dose inhaler) with slow-release (SR) terbutaline (5mg twice daily) plus; budesonide (BUD) lsqb;400mgr;g twice dailyrsqb; (administered via tablet and dry powder inhaler, respectively) for the treatment of Step Three asthma. The effects of the two combination regimens were assessed using lung function measurements, asthma symptoms, frequency of use of rescue bgr;2-agonist, overall efficacy, quality of life and tolerability. After a 2-week run-in period, 98 patients were randomised to receive salmeterolsol;BDP and 96 to receive SR-terbutalinesol;BUD for 8 weeks. Both treatment arms significantly improved all of the above parameters. However, the improvements observed in the salmeterolsol;BDP group were significantly better than those in the SR-terbutalinesol;BUD group for the following parameters: increase in spirometric and homemonitored peak expiratory flow (PEF), reduction in diurnal variation of PEF, reduction in use of daytime salbutamol as rescue medication, patients' and investigators' assessment of efficacy, and improvement in quality-of-life score using the Qualiteacute; de Vie Subjective de l'Asthmatique questionnaire. Both drug combinations were well tolerated, with slightly fewer patients experiencing treatment-related adverse events in the salmeterolsol;BDP group (9vs14percnt;). In conclusion, whilst both combination regimens achieved the goals set out in the management of asthma guidelines for Step Three asthma, greater control of asthma was observed using the salmeterolsol;BDP combination in this asthmatic patient population.
展开▼
